Issues related to cost to patients and insurance coverage have been reported as common barriers to the use of rituximab in patients with hematologic malignancies and for trastuzumab in patients with human epidermal growth factor receptor 2–amplified breast cancer, particularly among several EM countries (e.g., Brazil, Mexico, Turkey, and Russia) [13,15]. This evidence concerns the gene ERBB2 and breast carcinoma.